IGC powers Alzheimer’s and cannabis research with AI
August 14, 2023
IGC will aim for FDA fast-track designation after a Phase II trial investigating IGC-AD1 with AD patients concludes in Q1 2024.
IGC will aim for FDA fast-track designation after a Phase II trial investigating IGC-AD1 with AD patients concludes in Q1 2024.
Discover cutting-edge dementia science at AAIC Amsterdam. Breakthroughs and connections thrive as leading experts unite at the world’s largest conference on Alzheimer’s research.
Discover the remarkable innovation of IGC Pharma, highlighted in BENZINGA publication.
On May 14, Prof Govindaraju received the Government of India-instituted National Technology Award for outstanding contribution in commercialising innovative indigenous technologies from the Minister of State for Science and Technology and Earth Sciences, Dr Jitendra Singh.
SOURCE https://www.youtube.com/watch?v=gtE3SROFPXg
Hamsa Biopharma, which will take the drug †Christened TGR63†to trials through its parent company in the US, IGC Pharma, hopes it can eventually be made available in the market.
Researchers in India say they have discovered a promising drug target that may slow or even halt the progression of Alzheimer’s.
